News & Events
Sunshine Heart Announces Completion of Enrollment of 20 Patients for C-Pulse® Heart Assist System
05 / 04 / 2011
KaloBios Initiates Phase 1 Clinical Trial of KB004 in EphA3-Expressing Hematologic Malignancies
25 / 03 / 2011
ChemGenex to Align European and US Regulatory Strategies for Omacetaxine
05 / 01 / 2011
• Existing Marketing Authorization Application (MAA) for omacetaxine in T315I positive CML patients to be withdrawn • ChemGenex to submit a new MAA for omacetaxine in larger population of CML patients who have failed two or more tyrosine kinase inhibitors
ChemGenex Presents Updated Analysis at ASH on OMAPRO™in CML Patients who Failed Two or Three Approved TKI Drugs
06 / 12 / 2010
• New analysis of clinical data indicates that OMAPROTM could offer a new treatment approach for CML Patients who fail to respond to TKI therapy • OMAPROTM induced durable major cytogenetic responses in 33% of chronic phase patients who failed currently approved drugs
Sunshine Heart successfully completes $9.5 million capital raising with close of non-renounceable rights offer
03 / 12 / 2010
Euthymics Bioscience, Inc. Appoints Biotech Industry Veteran Walter Piskorski as Vice President, Technical Operations
18 / 11 / 2010
Company Moves into Permanent Headquarters in Cambridge
EUTHYMICS BIOSCIENCE, INC. NAMES BIOTECH EXECUTIVE TIMOTHY J. BARBERICH TO BOARD OF DIRECTORS
04 / 11 / 2010
Former Sepracor Founder and CEO Brings a History of Experience and Success in Drug Development and Commercialization
Steven Kesten, M.D., Leader in Pulmonary Medicine, Joins Uptake Medical as Vice President and Chief Medical Officer
01 / 11 / 2010
Displaying records 51-75 of 372